Heart and Blood Diseases

All Conditions

Rare Diseases

Phlebitis

Vascular Diseases

Peripheral Arterial Disease

Peripheral Vascular Diseases

Vasculitis

SeSAME Syndrome

Pharmaceutical Solutions

All Drugs and Chemicals

This arm will be administered 2 drops of sesame oil daily along the channeled vein, about 3 centimeters from the insertion point.

This arm will be administered 2 drops of physiological saline daily along the channeled vein, about 3 centimeters from the insertion point.

A peripheral venous catheter will be channeled to the patient admitted to the unit and who requires it. The indications included in the guide for channeling venous access of the Marqués de Valdecilla hospital will be followed.

Once the venous access has been channeled, it will be fixed with, leaving the puncture point visible for future monitoring.

The sesame oil chosen for the project is "Sesame bio - 100% pure vegetable oil from the Naissance brand.

To perform the procedure, two drops of sesame oil will be applied daily by the nurse in charge of the patient during the morning shift in the area about 2 cm above the insertion point and coinciding with the course of the vein channeled for intravenous therapy. A small massage of the area of application will be performed, with an approximate extension of 3x3cm, until its absorption. It will be left to dry in the air.

Sesame oil

After cannulation of the vein following the same procedure as explained in the intervention arm, patients belonging to the control arm will be administered two drops of saline solution.

Saline solution

Virginia Meneses Campos

Virginia Meneses

Cancer is a disease that, despite having a higher cure rate, is currently on the rise, with an increase in the number of diagnoses.

For the treatment of these patients a venous access is required, which in the first treatments is of peripheral insertion. These peripheral venous catheter in combination with the highly aggressive treatments for the veins are the cause of the appearance of chemical phlebitis.

Phlebitis is an inflammation caused by a combination of factors, whether chemical, perfusion of irritating medication; mechanical, due to the puncture site, type and fixation of the catheter and infectious, caused by the colonization of pathogenic agents whose origin is the skin and that migrate inward.

Phlebitis involves an injury to the wall of the vein, and consequently, the patient will also be at risk of thrombus formation, which in turn leads to thrombophlebitis, deep vein thrombosis or pulmonary embolism.

The existence of phlebitis involves intense and constant pain, with increased sensitivity and a sensation of heat and swelling.

With the use of topical sesame oil, and thanks to its anti-inflammatory properties, the investigators intend to study whether it is effective in preventing the appearance of phlebitis.

Effects of Topical Sesame Oil in the Prevention of Peripheral Venous Catheter Phlebitis: Clinical Trial.

Effects of Topical Sesame Oil in the Prevention of Chemotherapy-associated Peripheral Venous Catheter Phlebitis: Clinical Trial.

Sesame oil will be applied in the intervention groups, with the aim of assessing whether its application decreases the occurrence of phlebitis in oncology patients with irritating and high osmolarity intravenous medication.

Registration of other adverse effects related to chemotherapy administration through a peripheral catheter: extravasation, number of cannulations during admission, catheter duration and reason for withdrawal.

Hospital Universitario Marqués de Valdecilla

Principal Investigator

Neoplasms

Skin and Connective Tissue Diseases

Nervous System Diseases

Symptoms and General Pathology

Breast Neoplasms

Peripheral Nervous System Diseases

Sensation Disorders

Neurologic Manifestations

Acupuncture including scalp needling will be applied to selected points based on literature

Acupuncture twice a week for 6 weeks then one treatment a week for 4 weeks. Total 16 treatments in 10 weeks.

Acupuncture

Sivarama Vinjamury, MD, MAOM

The aim of this study is to collect preliminary data on the effectiveness of acupuncture for the treatment of CIPN in breast cancer patients.

Ideally 10 patients experiencing peripheral neuropathy due to chemotherapy from breast cancer treatment will be included in this study.They will receive 16 total acupuncture treatments over 10 weeks including various points based off of research and classical text and scalp acupuncture.

Acupuncture for CIPN in Breast Cancer Patients

Acupuncture for Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Patients- A Case Series

This is a 20-item self-report multidimensional CIPN specific scale that measures sensory, motor and autonomic symptoms of a 1-4 Likert scale.

Southern California University of Health Sciences

Professor

Substance Related Disorders

Neoplasm Metastasis

Neurotoxicity Syndromes

Breast Diseases

Paresthesia

Syndrome

Neoplastic Processes

Skin Diseases

Poisoning

Chemically-Induced Disorders

Antineoplastic Agents

Paclitaxel

Albumin-Bound Paclitaxel

2,2'-dithiodiethanesulfonic acid

Protective Agents

The treatment regimen administered in this study is a single IV doxe of paclitaxel (80 mg/m2) +/- Herceptin given over 1 hour and either BNP7787 (18.4 g/m2) or placebo given over 45 minutes each week. One treatment cycle = 8 weeks.

BNP7787

Placebo

The purpose of this study is to determine whether BNP7787 is effective in preventing or reducing neurotoxicity (nerve damage) caused by paclitaxel (Taxol®).

Chemotherapy induced toxicities are common and serious problems for many patients who receive treatment for cancer. Chemotherapy induced toxicities can adversely impact the quality of life and the ability of patients to continue treatment for their cancer. One such toxicity associated with the use of paclitaxel (Taxol®) is peripheral neurotoxicity.

Paclitaxel is an active drug in the treatment of metastatic breast cancer as first-line treatment and in patients with recurrent or refractory disease, including patients who have failed to respond to previous anthracycline therapy. Recent studies with paclitaxel using a weekly schedule of administration have demonstrated higher tumor response rates and disease free survival accompanied by a shift in the frequency of certain toxicities, increased dose intensity and a potential means to improve the treatment schedule of paclitaxel for improved patient benefit.

Paclitaxel induced neurotoxicity remains an important problem that limits the ability to improve the schedule of administration of this drug. To date, there is no effective or FDA approved therapy to prevent the development of or reduce the frequency or severity of paclitaxel-induced neurotoxicity.

BNP7787 is an investigational new drug that is undergoing development for chemoprotection of platinum and taxane associated common clinical toxicities, particularly the prevention of chemotherapy-induced neurotoxicity.

In this Phase 3 clinical trial the safety and effectiveness of BNP7787 in preventing or mitigating the frequency, severity, worsening of grade, time to onset, duration and discontinuation of therapy due to paclitaxel-induced neurotoxicity will be assessed in patients with metastatic breast cancer.

Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel

BNP7787 vs. Placebo for Prevention of Paclitaxel Neurotoxicity: A Double-Blind Multicenter Randomized Phase 3 Trial in Patients With Metastatic Breast Cancer

Lantern Pharma Inc. became Sponsor of Tavocept (BNP7787) IND 051014 as of March 26, 2019.

BioNumerik Pharmaceuticals, Inc.

Blood draws at baseline before systemic therapy. Blood draw then every 6 weeks for approximately 12 weeks.

Blood draw

William E. Gillanders, M.D.

This study is designed to determine whether molecular detection of breast cancer cells in the peripheral blood of Stage IV breast cancer patients is a clinically relevant predictor of progression-free and overall survival. Stage IV breast cancer patients who have measurable breast cancer metastases and are initiating a regimen of systemic therapy are eligible for enrollment. Multi-marker real-time RT-PCR analysis will be performed on peripheral blood specimens from 92 breast cancer patients and 120 healthy volunteers. Peripheral blood specimens from breast cancer patients will be obtained at the time of study entry (prior to initiation of systemic therapy) and at serial time points during follow-up. Subjects will be followed longitudinally until death, although the study has been powered so that the primary objective can be addressed after 12 months of follow-up. Healthy volunteers will be asked to provide a blood sample at time of enrollment but will not be followed.

A Study to Determine the Clinical Significance of Molecular Detection of Breast Cancer in the Blood of Stage IV Breast Cancer Patients

Peripheral Blood Molecular Staging of Breast Cancer: A Prospective Cohort Study Designed to Determine the Clinical Significance of Molecular Detection of Breast Cancer in the Peripheral Blood of Stage IV Breast Cancer Patients

Specifically, it is predicted that 60% of subjects with Stage IV breast cancer will have evidence of breast cancer cells in the peripheral blood by multi-marker real-time RT-PCR analysis, and that these subjects will experience a significantly decreased progression-free and overall survival.

Specifically, we will determine if molecular detection of circulating breast cancer cells after the initiation of systemic therapy is associated with a significantly decreased progression-free and overall survival.

Determine if baseline molecular marker expression levels are dependent on patient age, race, and/or the presence of benign breast disease.

National Institutes of Health (NIH)

Washington University School of Medicine

Digestive System Diseases

Colonic Diseases

Pain

Visceral Pain

Intestinal Diseases

Gastrointestinal Diseases

Nociceptive Pain

Analgesics

Central Nervous System Depressants

Gastrointestinal Agents

Herbal and Botanical

Analgesics, Opioid

Trimebutine

Hydrogen Sulfide

Parasympatholytics

Cola

GIC-1001 , 250 mg TID during 3 consecutive days + a last, 10th dose in the morning of Day 4 (colonoscopy day)

GIC-1001 , 375 mg TID during 3 consecutive days + a 10th dose in the morning of day 4 (colonoscopy day)

GIC-1001 , 500 mg TID during 3 consecutive days + a 10th dose in the morning of day 4 (colonoscopy day)

Placebo, TID during 3 consecutive days, + a 10 th dose in the morning of day 4 (colonoscopy day)

GIC-1001 oral tablet, white-coated, to be taken with water

GIC-1001

Mark V Larson, MD

Michael DeMicco, MD

Mark Lamet, MD

Taddese Desta, MD

Cynthia Schaeffer, MD

Vivek Gumaste, MD

Theadore Ptak, MD

Anand Sahai, MD

Umedchandra Shah, MD

Suryakanth R. Gurudu, MD

Robert Enns, MD

Narayanachar S Murali, MD

Vishal Gupta, MD

Albert Cohen, MD

Vitaly Fishbein, MD

Dennis Riff, MD

GIC-1001 is a novel, orally-administered, colonic analgesic drug developed as an alternative to i.v. sedation during full colonoscopy. It will be evaluated for efficacy and safety in a multi-center, randomized, double-blind, placebo controlled, dose-ranging, proof of concept Phase 2a trial. Up to 240 patients will receive one of 3 doses of GIC-1001 or its matching placebo. A pharmacokinetic evaluation will be carried out on a subset of patients (N: 24).

1. Study Objectives

   1.1 Primary objective: The primary objective of this Phase IIa study is to establish clinical Proof-of-Concept (POC) by providing clinically and statistically significant evidence that GIC-1001 is safe and effective in managing visceral pain in male and female patients who undergo sedation-free, full colonoscopy for preventive purposes.

   1.2 Secondary objectives: Secondary objectives will include the selection of the optimal dose of GIC-1001 from a safety/efficacy ratio point of view, establish a preliminary safety profile of the drug in patients, and obtain a preliminary general efficacy profile of GIC-1001 by assessing various secondary endpoints
2. Study Endpoints

   2.1 Primary endpoints:

   Visceral pain will be assessed using a 100-mm VAS, measured at various times and anatomical segments (N: 8) throughout the colon, i.e.:
   1. Prior to intra-rectal insertion of the endoscope;
   2. After insertion through the anus;
   3. After passage through the rectosigmoid segment;
   4. Immediately after passage through the splenic flexure;
   5. Immediately after passage through the hepatic flexure;
   6. Once the caecum is reached;
   7. Immediately after passage through the splenic flexure during scope withdrawal; and
   8. At the end of the procedure, once the colonoscope has been completely removed. Any additional episodes of pain experienced by the patient will also be assessed using the 100-mm VAS scale.

   The area under the curve (AUC) calculated from all serial measurements made will be used for statistical purposes, where the length of inserted colonoscope determines the VAS measurement's location.

   2.2 Secondary endpoints:
   1. Overall pain perception (100-mm VAS) at the end of the procedure;
   2. Time to reach the caecum with the endoscope (intubation time from rectum to caecum defined as time-to-caecum);
   3. Total examination time, defined at the time from introduction to removal of the colonoscope;
   4. Percentage of completed procedures;
   5. Endoscopist's perception of the adequacy of analgesia, difficulty of insertion, and amount of colonic spasm on insertion and withdrawal (five-point Likert scale);
   6. Use of rescue sedation (i.e. midazolam or midazolam followed by fentanyl)
   7. Safety as assessed by the incidence of treatment emergent adverse effects during the procedure and for 30 days after;
   8. Plasma determination of trimebutine and N-desmethyl-trimebutine moieties at GIC-1001 plasmatic steady state;
   9. Patient satisfaction with treatment (five-point Likert scale);
   10. Patient' willingness for repeat colonoscopy in the future (five-point Likert scale); and
   11. Safety of GIC-1001.
3. Study Design This is a randomized, double-blind, placebo-controlled parallel design 4-treatment arms study. Eligible patients will be randomized in a 1:1:1:2 ratio to one of 4 treatment arms: low (250 mg), mid (375 mg) or high (500 mg) dose of GIC-1001, or matching placebo. All potential study subjects will be screened and assessed for eligibility within maximum two (2) weeks prior to randomization. Bowel preparation will be performed using a polyethylene glycol (PEG) based regimen the night before the actual procedure.
4. Number of Clinical Sites: This trial will be conducted in both Canada and USA. Up to ten (10) clinical sites will participate in this trial. The lead Investigator for this trial is Dr Mark V. Larson MD, Head of Digestive Endoscopy, Mayo Clinic, Rochester MN, USA
5. Study population and sample size: Approximately 240 patients will be randomized in this study. Male and female patients having an indication for full colonoscopy, mainly for colorectal cancer screening and surveillance. Only naïve subjects, i.e. who never underwent colonoscopy before, will be eligible.
6. Inclusion Criteria See Eligibility Section
7. Exclusion Criteria See Eligibility Section
8. Study Drugs Administration and Schedule:

   GIC-1001, or its matching placebo will be administered as follows:
   1. One tablet TID on an empty stomach for three (3) consecutive days prior to colonoscopy.
   2. Last dose taken at the clinical site at least one (1) hour prior to beginning of procedure (endoscope insertion).
   3. Bowel preparation to be performed using PEG based regimen the day before the actual procedure.
   4. Three (3) different GIC-1001 dose levels will be studied:

      * 250 mg TID
      * 375 mg TID
      * 500 mg TID
      * Matching placebo TID
9. Concomitant Medications

   9.1 Prior to colonoscopy, the following medication will be permitted: Aspirin (ASA) at low levels for cardiovascular health, if dose and regimen stable for the last 6 months prior to colonoscopy.

   9.2 The following medications and foods will be prohibited:
   * Any prescription chronic analgesic narcotic, anti-spasmodic, anti-inflammatory medications are forbidden for 30 days prior to screening. (i.e. Washout ≥ 30 days)
   * Selective Serotonin Re-uptake Inhibitors (SSRIs) are forbidden for 30 days prior to screening, unless patient has been on a stable dose for 3 consecutive months prior to screening.
   * Over-the-counter analgesics, or anti-inflammatory medication, oral or topical used for acute pain treatment must be washed out for ≥ 7days prior to screening.
   * Acute or as needed prescription or non-prescription anti-inflammatory and/or analgesic treatment within one (1) week prior to colonoscopy.
   * Use of bowel stimulant laxatives, such bisacodyl, within one (1) week preceding randomization.
   * Use of antidiarrheic medication, such as diphenoxylate, loperamide, kaopectate or bismuth salts, within one (1) week preceding randomization.
   * Administration of barium enema within two (2) weeks preceding randomization.
   * Colonic irritant beverages or foods, such as caffeine-containing beverages (e.g. coffee, Coca-Cola), spices, as well as foods containing seeds (i.e. tomatoes, strawberries, kiwis, raspberries) within 24 hours preceding colonoscopy.
   * Use of any other investigational drug is prohibited unless discontinued, within at least 30 days prior to randomization.
   * Additionally, Prior and Concomitant Medications are to be recorded in the CRF starting 30 days prior to Screening Visit CLV1.
10. Efficacy Evaluation: Colonic analgesic clinical efficacy of GIC-1001 will be measured using a continuous, horizontal 100-mm VAS, at pre-determined times and colonic anatomical segments. At least 8 measurements will be done by the participating patients themselves (see Primary Endpoint section). Subjects will receive proper instructions on the use of the VAS prior to colonoscopy. Overall experience of visceral pain (if any) will be evaluated using the AUC constructed from all calculated VAS self-measurements for each patient. Additional, secondary, efficacy endpoints will also be measured, including time-to-caecum, colonoscopy completion rate and antispasmodic activity.
11. Safety Evaluation: Safety will be assessed using the performance of physical exams, ECG, various laboratory safety tests and the occurrence of adverse events. AEs will be mapped to MedDRA, version 16.
12. Sample Size Considerations: It has been reported in the medical literature that a MCID range of 10-15 mm on the 100-mm VAS is clinical significant in the evaluation of colonoscopy-related visceral pain. Using this value, with an alpha of 0.05 and a beta of 0.9, about 50 patients would be needed in each active arm considering a 90-patient placebo arm. Total study sample size is then estimated at approximately 240 randomized patients.
13. Statistical Analysis: The primary outcome measure will be the mean 100-mm VAS AUC in each treatment arm.

A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy

A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study of GIC-1001 for the Management of Visceral Pain in Subjects Undergoing Sedation-Free, Full Colonoscopy

The Primary Outcomes Measure was the pain VAS 100-mm AUC (0mm = no pain; 100mm = worst pain), constructed from serial pain VAS measurements performed during colonoscopy. At least 8 pain VAS measurements were made, and the length of the colonoscope inserted (or removed on the way out) was recorded at every measurement. The X-axis of the VAS versus anatomical locations was defined accordingly: each VAS value corresponded to a relative length of inserted colonoscope (d/2Lc) of the X axis, where d was the actual length of the inserted colonoscope and 2Lc represented twice the total length of the colon examined (Lc). Before scope insertion the X value equaled zero. Once the caecum was reached, the X value was 0.5. Upon complete removal of the endoscope, the X value was 1. This allowed standardization of colonic length between study subjects. Visceral pain AUC (mm) was calculated from all serial measurements, where the length of inserted colonoscope determined the VAS measurement's location

Time to Caecum is the time taken by the physician to reach the caecum with the colonoscope, from the insertion in the anus. Time to Caecum was measured during colonoscopy, for which total duration of colonoscopy ranged between a minimum of 5.00 and a maximum of 50.10 minutes.

Qualitative outcome: colonoscopy completion is defined as a procedure performed entirely, from initial anal insertion, reaching of caecum, and complete removal of the scope. Completion rate is then the number of patient (%) with a complete colonoscopy (up to the caecum) divided by the number of trial participants.

A pharmacokinetic (PK) analysis was carried out on the first 24 patients randomized, equally distributed between treatment groups; 18 patients were assigned to active treatment

Defined as the time from endoscope insertion to complete removal of the endoscope; measured in minutes

Endoscopist's perception of the adequacy of analgesia, difficulty of insertion and withdrawal measured on a five-point Likert scale: Strongly Agree, Agree, Agree nor Disagree, Disagree, Strongly Disagree

Endoscopist's perception of the amount of colonic spasm on insertion and withdrawal measured on five-point Likert scale according to the following: Strongly Agree, Agree, Agree nor Disagree, Disagree, Strongly Disagree

Patients' willingness for repeat colonoscopy, was assessed with the Patient Willingness to Repeat Experience (P.W.R.E.) questionnaire (1 question), asking patients to rate their willingness to repeat the procedure according to a 5-point Likert scale: Strongly Agree, Agree, Agree nor Disagree, Disagree, Strongly Disagree. The P.W.R.E was administered after the colonoscopy during subject recovery.

Subject satisfaction and acceptability of the colonic analgesia modality offered by GIC-1001 was assessed with the Patient Global Impression of Abdominal Pain (P.G.I.A.P.) (1 question), asking patients to rate their pain during the procedure according to a 5-point Likert scale: Absent, Mild, Moderate, Severe, Intolerable. The P.G.I.A.P was administered after the colonoscopy during subject recovery.

JSS Medical Research Inc.

Algorithme Pharma Inc

gicare Pharma Inc.

Safety was assessed via performance of physical exams, vital signs, 12-lead ECG, laboratory safety tests (hematology, biochemistry and urinalysis) and the occurrence of adverse events.

GIC-1001 , 250 mg TID during 3 consecutive days + a last, 10th dose in the morning of Day 4 (colonoscopy day)

GIC-1001: GIC-1001 oral tablet, white-coated, to be taken with water

GIC-1001 Low Dose

GIC-1001 , 375 mg TID during 3 consecutive days + a 10th dose in the morning of day 4 (colonoscopy day)

GIC-1001: GIC-1001 oral tablet, white-coated, to be taken with water

GIC-1001 Mid-dose

GIC-1001 , 500 mg TID during 3 consecutive days + a 10th dose in the morning of day 4 (colonoscopy day)

GIC-1001: GIC-1001 oral tablet, white-coated, to be taken with water

GIC-1001 , High Dose

Placebo, TID during 3 consecutive days, + a 10 th dose in the morning of day 4 (colonoscopy day)

GIC-1001: GIC-1001 oral tablet, white-coated, to be taken with water

GIC-1001 Matching Placebo

Total

Age, Continuous

Sex: Female, Male

Asian/Oriental

Black

Caucasian

Hispanic

Other

Race/Ethnicity, Customized

Demographics provided for the Full Analysis Set (FAS; N=262), defined as all randomized patients who received at least one dose of study drug, had a baseline and at least one post-baseline VAS rating.

Patrick Colin

AUC Censored (Standardized)- PP Population

AUC- censorsed (standardized); FAS

AUC LOCF (standardized); FAS

AUC- censorsed (standardized); PP

AUC LOCF (standardized); PP

Primary endpoint assessed in the FAS (randomized patients who received at least one dose of study drug, had a baseline and at least one post-baseline VAS rating; N=262) and PP analysis sets (randomized patients in the FA population with ≥80% treatment compliance, who had at least 6/8 VAS ratings and no major protocol deviations; N=213)

Measurements of Visceral Pain, Using a 100-mm Visual Analog Scale (VAS)

FAS (randomized patients who received at least one dose of study drug, had a baseline and at least one post-baseline VAS rating; N=262)

Time to Caecum

Colonoscopy Completion Rate (%)

Plasma Concentration- Trimebutine

Plasma Concentration-N-Desmethyl-Trimebutine

Trimebutine and N-Desmethyl-Trimebutine plasma concentrations were assessed in all arms, with the exception of placebo

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Effects of Topical Sesame Oil in the Prevention of Peripheral Venous Catheter Phlebitis: Clinical Trial.	NCT06375850	Phlebitis	Sesame oil Saline solution	18 Years -	Hospital Universitario Marqués de Valdecilla
Acupuncture for CIPN in Breast Cancer Patients	NCT02615678	Sensation Disor... Neuropathy	Acupuncture	18 Years -	Southern California University of Health Sciences
Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel	NCT00039780	Breast Neoplasm... Breast Diseases Metastases, Neo...	BNP7787 Placebo	18 Years -	BioNumerik Pharmaceuticals, Inc.
A Study to Determine the Clinical Significance of Molecular Detection of Breast Cancer in the Blood of Stage IV Breast Cancer Patients	NCT00355316	Breast Neoplasm...	Blood draw	18 Years -	Washington University School of Medicine
A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy	NCT01926444	Pain Cancer Colonic Disease...	GIC-1001	40 Years - 70 Years	gicare Pharma Inc.
Effects of Topical Sesame Oil in the Prevention of Peripheral Venous Catheter Phlebitis: Clinical Trial.	NCT06375850	Phlebitis	Sesame oil Saline solution	18 Years -	Hospital Universitario Marqués de Valdecilla
A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy	NCT01926444	Pain Cancer Colonic Disease...	GIC-1001	40 Years - 70 Years	gicare Pharma Inc.
A Study to Determine the Clinical Significance of Molecular Detection of Breast Cancer in the Blood of Stage IV Breast Cancer Patients	NCT00355316	Breast Neoplasm...	Blood draw	18 Years -	Washington University School of Medicine
Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel	NCT00039780	Breast Neoplasm... Breast Diseases Metastases, Neo...	BNP7787 Placebo	18 Years -	BioNumerik Pharmaceuticals, Inc.

Spots Global Cancer Trial Database for peripheral

Every month we try and update this database with for peripheral cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for peripheral

Every month we try and update this database with for peripheral cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for peripheral cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.